Oxford Science Enterprises

Oxford Science Enterprises (OSE) is a UK-based venture capital firm specializing in spinouts from the University of Oxford. Founded in 2015, OSE partners with the university to identify, fund, and build transformative businesses across life sciences, health tech, and deep tech sectors. The firm has raised over £850 million since its inception, investing in more than 80 companies. OSE's portfolio includes companies like Vaccitech, which developed the Oxford/AstraZeneca COVID-19 vaccine, and Base Genomics, acquired by Exact Sciences for $410 million. The firm provides comprehensive support to its portfolio companies, including strategic business-building, operational support, and access to a global network of entrepreneurs and advisers. OSE's unique partnership with the University of Oxford allows it to access cutting-edge research and collaborate closely with academic founders to commercialize innovative technologies. The firm's patient capital model enables it to support companies through various stages of development, from seed funding to IPOs and trade exits. OSE's commitment to fostering a dynamic ecosystem has led to the creation of over 2,000 highly skilled jobs across its portfolio and the addition of over 55,000 square feet of dedicated lab and start-up space. The firm's diverse investor base includes institutional investors, sovereign wealth funds, family offices, and pension funds, reflecting strong confidence in OSE's ability to translate academic research into successful commercial ventures.

Strong link to University of Oxford research, Innovative technology with potential for global impact, Experienced management team, Scalable business model, Clear path to commercialization